|
|
|
| Study on the experience of treatment of ovarian cancer with Shen Minhe’s compound fuling decoction |
| HUANG Hong TAO Fangfang |
School of Basic Medical Sciences, Zhejiang Chinese Medicine University, Zhejiang Province, Hangzhou 310053, China
|
|
|
|
Abstract Ovarian cancer is a reproductive malignant tumor in women with a high incidence rate and mortality. In the treatment of ovarian cancer, traditional Chinese medicine not only has an anti-tumor effect and can strengthen the body’s resistance to eliminate pathogenic factors, but also reduce the side effects of modern medical treatment. Shen Minhe, a renowned traditional Chinese medicine doctor in Zhejiang Province engaged in the clinical practice of tumors with traditional Chinese medicine for more than 30 years, has accumulated a lot of experience in tumor diagnosis and treatment, and gradually formed his own unique method of syndrome differentiation and diagnosis and treatment. The Compound Fuling Decoction is an effective prescription for the treatment of ovarian cancer summarized by Director Shen Minhe in his long-term clinical practice. This paper introduces the origin of the prescription, functions of medicines in the prescription, addition and subtraction of medicines, and other relevant information, and summarizes the academic ideas emphasized by Director Shen Minhe in his clinical practice such as emotion and diet adjustment and protection of spleen and stomach. At the same time, a case study is used to illustrate the experience of the clinical application of Compound Fuling Decoction.
|
|
|
|
|
|
[1] World Health Organization. Global Cancer Observatory [EB/ OL]. [2021-07-29]. https：//gco.Iarc.fr/today/online-analysis-table.
[2] Jenks S. Setting the bar higher for ovarian cancer survival [J]. J Natl Cancer Inst，2014，106（2）：dju037.
[3] Siegel RL，Miller KD，Fuchs HE，et al. Cancer Statistics，2021 [J]. CA：A Cancer Journal for Clinicians，2021，71（1）：7-33.
[4] 张星星，刘琦.中医药治疗卵巢癌新进展[J].医学理论与实践，2022，35（6）：942-944..
[5] 玄海阳，李秀荣.中医药治疗卵巢癌研究概况[J].山东中医药大学学报，2022，46（2）：271-276.
[6] 杨爽，沈影，韩凤娟.中医药对卵巢癌的治疗作用及研究进展[J].辽宁中医杂志，2021，48（10）：202-207.
[7] 徐成贺.金匮要略[M].郑州：河南科学技术出版社，2019：403-404.
[8] 徐忠可.金匮要略论注[M].邓明仲，张家礼，点校.北京：人民卫生出版社，1993：298-300.
[9] 陆超颖，丁梦磊，蔡淑慧，等.附子生物碱类成分分析及其抗肿瘤机制初探[J].南京中医药大学学报，2021，37（5）：720-729.
[10] 闫霜，王雅莉.茯苓多糖影响卵巢癌细胞耐药性的机制[J].西北药学杂志，2022，37（3）：94-100.
[11] 马艳春，范楚晨，冯天甜，等.茯苓的化学成分和药理作用研究进展[J].中医药学报，2021，49（12）：108-111.
[12] 郭宇航，张莉丹，王伊楠，等.墓头回水提液凉血止血作用及机制评价研究[J].中药药理与临床，2022，38（1）：92-98.
[13] 杨玉赫，徐雪娇，李陈雪，等.赤芍化学成分及药理作用研究新进展[J].化学工程师，2021，35（9）：42-44，31.
[14] 黄宏.沈敏鹤主任治疗卵巢癌用药规律及复方附苓颗粒干预GSK-3β抑制卵巢癌转移的分子机制研究[D].杭州：浙江中医药大学，2017.
[15] Ruan S，Zhang H，Tian X，et al. PHD Finger Protein 19 Enhances the Resistance of Ovarian Cancer Cells to Compound Fuling Granule by Protecting Cell Growth，Invasion， Migration，and Stemness [J]. Front Pharmacol，2020，11：150.
[16] 巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社，1997：17.
[17] 李中梓.医宗必读[M].天津：天津科学技术出版社，1999：256.
[18] 徐成贺主编.金匮要略[M].郑州：河南科学技术出版社，2019.01：427.
[19] 巢元方.诸病源候论[M].沈阳：辽宁科学技术出版社，1997：98.
[20] 陈实功.外科正宗[M].上海：上海科学技术出版社，1989：173-176.
[21] 陈素庵，陈文昭补解.陈素庵妇科补解[M].上海：上海科学技术出版社，1983：35-38.
[22] （唐）房玄龄注；（明）刘绩补注；刘晓艺校点.管子[M].上海：上海古籍出版社，2015：272.
[23] 吴霜霜，戚益铭，阮善明.沈敏鹤用阴阳平衡观指导治疗三焦肿瘤经验[J].中华中医药杂志，2015，12：4346- 4349.
[24] 南京中医学院（南京中医学大学编著）.伤寒论[M].上海：上海科学技术出版社，2018：261.
[25] 孙思邈.千金方[M].刘更生，等点校.北京：华夏出版社，1993：367. |
|
|
|
